SOURCE: Prima BioMed

January 30, 2014 21:20 ET

Prima BioMed to Present at the 16th Annual BIO CEO & Investor Conference

SYDNEY, AUSTRALIA--(Marketwired - Jan 30, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", "the Company") has announced today that Matthew Lehman, its Chief Executive Officer, will present at the 16th Annual BIO CEO & Investor Conference on Monday, 10 February 2014 in New York City at the Waldorf Astoria Hotel. Mr. Lehman will provide an overview of the Company and its corporate activities and will be available to participate in one-on-one meetings.

The Company's presentation is scheduled to begin at 10:30am Eastern US Time and will be available via a live audio webcast. To access the webcast, please go to http://www.veracast.com/webcasts/bio/ceoinvestor2014/93126297249.cfm. A replay of the webcast will be available for 90 days following the presentation and may be accessed by visiting Prima BioMed's website.

About Prima BioMed
Prima BioMed is a globally active leader in the development of personalized immunocellular therapeutic products for the treatment of cancer. Prima is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Prima's lead product is CVac™, an autologous dendritic cell-based product currently in clinical trials. www.primabiomed.com.au

Contact Information

  • For further information please contact:

    USA Investor/Media:
    Ms. Jessica Brown
    Prima BioMed Ltd.
    +1 (919) 710-9061
    Email Contact

    Australia Investor/Media:
    Mr. James Moses
    Mandate Corporate
    +61 (0) 420 991 574
    Email Contact

    Europe Investor/Media:
    Mr. Axel Muhlhaus
    edicto GmbH
    +49 (0) 69 905505-52
    Email Contact